Abbott Gets Approval For Liquid Injection Of Synagis For RS-Virus Prevention
This article was originally published in PharmAsia News
Executive Summary
Abbott Japan announced Aug. 15 that it has received approval for the liquid injection of Synagis (palivizumab) for the prevention of respiratory tract virus.